Sam Life Sciences Profile
Key Indicators
- Authorised Capital ₹ 4.00 Cr
as on 29-07-2024
- Paid Up Capital ₹ 1.42 Cr
as on 29-07-2024
- Company Age 10 Year, 6 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 17.88 Cr
as on 29-07-2024
- Satisfied Charges ₹ 7.50 Cr
as on 29-07-2024
- Revenue -77.98%
(FY 2023)
- Profit -158.69%
(FY 2023)
- Ebitda -51.41%
(FY 2023)
- Net Worth -9.16%
(FY 2023)
- Total Assets 23.69%
(FY 2023)
About Sam Life Sciences
The Company is engaged in the Life Sciences Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 4.00 Cr and a paid-up capital of Rs 1.42 Cr.
The company currently has active open charges totaling ₹17.88 Cr. The company has closed loans amounting to ₹7.50 Cr, as per Ministry of Corporate Affairs (MCA) records.
Bhimaji Sabale and Rekha Sabale serve as directors at the Company.
- CIN/LLPIN
U74900PN2014PTC151833
- Company No.
151833
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
16 Jul 2014
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Pune
Industry
Company Details
- Location
Pune, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Sam Life Sciences?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Bhimaji Sabale  | Director | 16-Jul-2014 | Current |
| Rekha Sabale | Director | 16-Jul-2014 | Current |
Financial Performance of Sam Life Sciences.
Sam Life Sciences Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 77.98% decrease. The company also saw a substantial fall in profitability, with a 158.69% decrease in profit. The company's net worth dipped by a decrease of 9.16%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Sam Life Sciences?
In 2023, Sam Life Sciences had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Earthchem Laboratories Private LimitedActive 18 years 5 monthsBhimaji Sabale and Rekha Sabale are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Indian Bank Creation Date: 20 Aug 2022 | ₹5.25 Cr | Open |
Indian Bank Creation Date: 11 Nov 2021 | ₹9.74 M | Open |
Indian Bank Creation Date: 14 Jul 2020 | ₹7.71 M | Open |
How Many Employees Work at Sam Life Sciences?
Unlock and access historical data on people associated with Sam Life Sciences, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Sam Life Sciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Sam Life Sciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
